CiceroDx Release: "Breakthrough" Test For Unexplained Infertility Now Available
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--CiceroDx, Inc., a women’s healthcare diagnostic company, today announced the release of ReceptivaDx, a test panel designed for women with unexplained infertility. The ReceptivaDx test seeks to help In Vitro Fertilization (IVF) centers and other healthcare providers identify barriers to implantation, including one of the key underlying causes of unexplained infertility -- endometriosis.
With more than six million women in the U.S. affected by infertility issues, IVF centers across the country seek to help these women conceive and give birth. Unfortunately, it is estimated that 15-30% of the women undergoing infertility evaluation have no cause identified and are less likely to have a successful IVF experience. According to the American Society of Reproductive Medicine, endometriosis is associated with up to 50% of all cases of unexplained infertility.
Current diagnostic techniques for endometriosis require the use of laparoscopy, an invasive and expensive surgical procedure. With the introduction of the ReceptivaDx assay, endometriosis can be identified quickly and cost-effectively using an endometrial biopsy sample collected during a routine office visit. Early detection of endometriosis can help guide treatment for IVF centers, ensuring higher success rates and alleviating the financial and emotional burden of a family attempting to conceive.
“As one of the early adopters of the ReceptivaDx test, our experience has exceeded my expectations,” said Dr. Aimee Evazzadeh, a reproductive endocrinologist based in the San Francisco Bay Area. “We can now identify and treat women with early endometriosis who might have gone undetected before. For our patients, this has led to improved success rates, reduced costs and the avoidance of multiple IVF cycles.”
Over 60,000 babies are born each year as a result of IVF procedures in the U.S. with procedures failing to achieve success in about half of all cases. The need for a cost-effective test to help identify endometriosis as a cause for failure is the driver behind the launch of ReceptivaDx. CiceroDx holds the exclusive license to market and distribute the test for its use in unexplained infertility.
“ReceptivaDx is a breakthrough test and provides a unique, enhanced screening opportunity in women with unexplained infertility and unidentified causes of implantation failure,” said Bruce Lessey, M.D. and Ph.D., a pioneer in reproductive medicine and related research and a scientific advisor for CiceroDx.
“Our mission at CiceroDx is to ensure we deliver the most accurate and cost-effective diagnostic tools for doctors and families looking for answers to unexplained infertility and implantation failure,” said Chris Jackson, CEO of CiceroDx. “Helping resolve infertility issues is just the first step. Our goal is to help clinicians better detect endometriosis in the millions of women who suffer from this silent epidemic every day.”
According to endometriosis.org, an international non-profit group, endometriosis affects an estimated 176 million women worldwide regardless of their ethnic and social background. Many remain undiagnosed and are therefore not treated.
The ReceptivaDx test for unexplained infertility costs $790 with results available in 3 to 5 days. The test is currently offered in over 75 IVF centers across the U.S., Canada, Europe and South America.
For more information, please visit www.ReceptivaDx.com
CiceroDx is a medical diagnostic company located in Huntington Beach, Calif. ReceptivaDx is the company’s first test panel in the area of unexplained infertility. CiceroDx intends to expand their offering globally and is investing in continued research in the field. For more information, visit http://www.receptivadx.com/about-cicerodx.